Marinus Pharmaceuticals (NASDAQ:MRNS) Trading 8% Higher

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares traded up 8% during trading on Thursday . The stock traded as high as $3.97 and last traded at $3.92. 432,381 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 646,876 shares. The stock had previously closed at $3.63.

Several research analysts have recently commented on the company. Zacks Investment Research downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $24.50 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, May 1st. Cantor Fitzgerald reissued a “buy” rating and issued a $22.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, May 1st. ValuEngine raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Finally, Jefferies Financial Group assumed coverage on Marinus Pharmaceuticals in a report on Tuesday, March 5th. They issued a “buy” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. Marinus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $14.93.

The stock has a fifty day simple moving average of $4.28. The stock has a market capitalization of $218.12 million, a PE ratio of -4.61 and a beta of 3.17.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). Analysts forecast that Marinus Pharmaceuticals Inc will post -0.86 earnings per share for the current fiscal year.

In other Marinus Pharmaceuticals news, CFO Edward F. Smith sold 24,211 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $5.03, for a total transaction of $121,781.33. Following the transaction, the chief financial officer now owns 20,097 shares of the company’s stock, valued at approximately $101,087.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 5.10% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of MRNS. Gabelli Funds LLC increased its holdings in Marinus Pharmaceuticals by 58.8% during the 1st quarter. Gabelli Funds LLC now owns 27,000 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 10,000 shares during the period. Rhumbline Advisers increased its holdings in shares of Marinus Pharmaceuticals by 15.8% in the 1st quarter. Rhumbline Advisers now owns 55,755 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 7,592 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Marinus Pharmaceuticals by 1,465.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,047 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 9,405 shares during the last quarter. Bailard Inc. bought a new position in shares of Marinus Pharmaceuticals in the 1st quarter worth $138,000. Finally, 683 Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 22.7% in the 4th quarter. 683 Capital Management LLC now owns 1,350,000 shares of the biopharmaceutical company’s stock worth $3,875,000 after buying an additional 250,000 shares during the last quarter. 63.35% of the stock is currently owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Article: How can you know how many shares are floating?

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.